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EDITORIALA New Positive Feedback Circuit in the Fibrosis–Cancer Axis for
Male Liverserotonin (also known as 5-hydroxytryptamineS[5-HT]) is a small-molecule neurotransmitter that
was identified in a series of studies conducted between
1935 and 1953 because of its capacity to induce contrac-
tions in the intestine and blood vessels. A plethora of
functions for the serotonin system have been described,
including regulation of mood, blood clotting, gut motility,
systemic energy homeostasis, and tissue repair. Serotonin
is synthesized from the essential amino acid tryptophan
via tryptophan hydroxylase (TPH) in the brain and
enterochromaffin cells of the gastrointestinal tract. Gut-
produced serotonin then actively is taken up by platelets
and travels in the blood stream where it can be released on
demand.
Seminal studies in the past decade have identified
several important roles for the serotonin system in liver
homeostasis and disease. An elegant study in 2006
introduced a new paradigm for platelet-derived serotonin
in promoting liver regeneration by acting directly on
hepatocytes (via the hepatocyte 5-HT2A receptor).
1 A
subsequent study in 2011 established a more complex
model, showing the antiregenerative and profibrogenic
function of serotonin in normal and diseased liver
through 5-HT2B receptor activation in stellate cells and
production of transforming growth factor (TGF)-b1.2
These studies described an integral role for the seroto-
nin system in controlling the balance between hepatic
regeneration and fibrosis. Given that inflammation and
fibrosis provide a permissive microenvironment for the
emergence of tumorigenic hepatocytes and that hepato-
cellular carcinoma is the third-leading cause of cancer
death with a poor prognosis and very limited therapeutic
options, a key follow-up study was to interrogate the role
of serotonin-related pathways in the development of
hepatocellular carcinoma in models with progressive liver
fibrosis. This is even more important in light of recent
findings about the reliability of serum serotonin as a
potential clinical biomarker for the diagnosis and staging
of liver cancer.3
In this issue of Cellular and Molecular Gastroenterology
and Hepatology, Yang et al have described4 a new positive
feedback circuit for serotonin system components in
fueling the fibrosis–cancer axis in diseased liver.4 The
authors also have reported that this loop is essential for
sexual dimorphism in liver cancer.4 To investigate this
topic, they used a transgenic zebrafish model with the
krasV12 mutation and showed accelerated fibrosis and
cancer in males. Subsequently, through a series of phar-
macologic interventions, they discovered a 2-way inter-
cellular communication loop between hepatocytes andCelluactivated stellate cells during the progression of liver
disease. In this circuit, hepatocytes produce serotonin via
up-regulation of TPH1. The induced serotonin stimulates
activated stellate cells via the 5-HT2B receptor, inducing
TGF-b1 synthesis. The production of TGF-b1 in this model
further promotes stellate cell activation, fibrosis, and
carcinogenesis. Strikingly, 5-HT2B-receptor–induced TGF-
b1 signals back to hepatocytes, stimulating them to up-
regulate TPH-1 and serotonin synthesis further. Hence,
the 2-way intercellular cross-talk acts as a positive feed-
back loop to maintain or enhance the phenotype of both
hepatocytes and stellate cells. The investigators discov-
ered that several components of this circuit (eg, TPH-1,
serotonin, 5-HT2B receptor, and TGF-b1) are increased
in the liver of male fish. When they studied samples from
human patients, they found similar sexual dimorphism in
both serotonin and TGF-b1, especially in inflammation
and cirrhosis samples.
Similar to every interesting study, this one raises several
new questions. For example, it is not obvious what factor(s)
turn on the circuit in an injured liver in a sex-dependent
fashion. In addition, we do not know which cell type (stel-
late cells or hepatocytes) begins the cross-talk. We do know
that estrogen inhibits interleukin 6 production by Kupffer
cells, which results in a reduced cancer risk in females.5 One
intriguing possibility is that the serotonin feedback loop
cooperates with inflammatory signaling molecules such as
interleukin 6 and acts as a signal amplifying circuit to
further increase sex disparity in liver cancer. In fact, several
studies have shown cross-talk between the serotonin
system and inflammatory pathways including Toll-like
receptors. Until now, it was thought that platelets were
the key players in serotonin release in injured liver, and
gut-produced serotonin was the main source. This study
argues that intrahepatic serotonin synthesis may be equally
important.
Potent and selective pharmacologic agents that target
the serotonin system are already in the clinic. 5-HT2B
antagonists are being studied as treatments for several
conditions including pulmonary hypertension and
chronic heart disease.6 Therefore, this class of drug may
provide an attractive option for controlling the fibro-
sis–cancer axis in human liver disease. However, it still
is unclear at what stages of disease in human beings it
would be most effective to target the serotonin system.
Regardless, the article by Yang et al4 provides us with
important evidence that the serotonin system is a key
player in liver fibrosis and cancer, and they identify it as
an important therapeutic target that is worthy of further
investigation.lar and Molecular Gastroenterology and Hepatology 2017;3:301–302
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